JP2002516109A - マイコバクテリアのｎ−アセチルトランスフェラーゼ - Google Patents
マイコバクテリアのｎ−アセチルトランスフェラーゼInfo
- Publication number
- JP2002516109A JP2002516109A JP2000551009A JP2000551009A JP2002516109A JP 2002516109 A JP2002516109 A JP 2002516109A JP 2000551009 A JP2000551009 A JP 2000551009A JP 2000551009 A JP2000551009 A JP 2000551009A JP 2002516109 A JP2002516109 A JP 2002516109A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- acetyltransferase
- arylamine
- mycobacterial
- nat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101710202061 N-acetyltransferase Proteins 0.000 title claims description 195
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 101
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 79
- 108020005224 Arylamine N-acetyltransferase Proteins 0.000 claims abstract description 73
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 102000006809 Arylamine N-Acetyltransferase Human genes 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 61
- 239000000758 substrate Substances 0.000 claims abstract description 35
- 241000187480 Mycobacterium smegmatis Species 0.000 claims abstract description 31
- 239000003926 antimycobacterial agent Substances 0.000 claims abstract description 29
- 102000004190 Enzymes Human genes 0.000 claims abstract description 28
- 108090000790 Enzymes Proteins 0.000 claims abstract description 28
- 230000001355 anti-mycobacterial effect Effects 0.000 claims abstract description 22
- 239000003446 ligand Substances 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 238000009472 formulation Methods 0.000 claims abstract description 9
- 238000012216 screening Methods 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 7
- 206010062207 Mycobacterial infection Diseases 0.000 claims abstract description 6
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims abstract description 6
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 62
- 229960003350 isoniazid Drugs 0.000 claims description 55
- 239000012634 fragment Substances 0.000 claims description 49
- 230000000694 effects Effects 0.000 claims description 43
- 239000000523 sample Substances 0.000 claims description 29
- 150000004982 aromatic amines Chemical class 0.000 claims description 25
- 150000001413 amino acids Chemical group 0.000 claims description 24
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 22
- 238000006640 acetylation reaction Methods 0.000 claims description 21
- 108020004414 DNA Proteins 0.000 claims description 19
- 230000021736 acetylation Effects 0.000 claims description 18
- 241000186359 Mycobacterium Species 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 230000012010 growth Effects 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 102000007079 Peptide Fragments Human genes 0.000 claims description 9
- 108010033276 Peptide Fragments Proteins 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 8
- 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 102000014914 Carrier Proteins Human genes 0.000 claims description 7
- 230000001086 cytosolic effect Effects 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 230000000692 anti-sense effect Effects 0.000 claims description 6
- 108091008324 binding proteins Proteins 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 6
- 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 claims description 5
- 101900155084 Mycobacterium tuberculosis Arylamine N-acetyltransferase Proteins 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 108020002494 acetyltransferase Proteins 0.000 claims description 5
- 229940034014 antimycobacterial agent Drugs 0.000 claims description 5
- 238000000527 sonication Methods 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 241000186366 Mycobacterium bovis Species 0.000 claims description 3
- 241000186362 Mycobacterium leprae Species 0.000 claims description 3
- 108010064998 N-acetyltransferase 1 Proteins 0.000 claims description 3
- 102000005421 acetyltransferase Human genes 0.000 claims description 3
- 229960000860 dapsone Drugs 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 150000002429 hydrazines Chemical class 0.000 claims description 3
- WUBBRNOQWQTFEX-UHFFFAOYSA-M 4-aminosalicylate(1-) Chemical compound NC1=CC=C(C([O-])=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-M 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002001 ethionamide Drugs 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 description 68
- 201000008827 tuberculosis Diseases 0.000 description 67
- 101150087123 nat gene Proteins 0.000 description 44
- 230000014509 gene expression Effects 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 19
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 239000002671 adjuvant Substances 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 238000003209 gene knockout Methods 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 239000006166 lysate Substances 0.000 description 11
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 10
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 229930027917 kanamycin Natural products 0.000 description 9
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 9
- 229960000318 kanamycin Drugs 0.000 description 9
- 229930182823 kanamycin A Natural products 0.000 description 9
- 239000004202 carbamide Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- -1 aromatic hydrazines Chemical class 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229960004050 aminobenzoic acid Drugs 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 108020005544 Antisense RNA Proteins 0.000 description 4
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011330 nucleic acid test Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 101710176159 32 kDa protein Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 102100038108 Arylamine N-acetyltransferase 1 Human genes 0.000 description 2
- 101800001415 Bri23 peptide Proteins 0.000 description 2
- 102400000107 C-terminal peptide Human genes 0.000 description 2
- 101800000655 C-terminal peptide Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 101000884385 Homo sapiens Arylamine N-acetyltransferase 1 Proteins 0.000 description 2
- 101001034811 Homo sapiens Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 2
- 101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 description 2
- 101150005343 INHA gene Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 101150050863 T gene Proteins 0.000 description 2
- 239000012345 acetylating agent Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229960004909 aminosalicylic acid Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 101150036080 at gene Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 102000054560 human NAT2 Human genes 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009670 mycobacterial growth Effects 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 102220201851 rs143406017 Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- CYSPWCARDHRYJX-UHFFFAOYSA-N 9h-fluoren-1-amine Chemical compound C12=CC=CC=C2CC2=C1C=CC=C2N CYSPWCARDHRYJX-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000983155 Homo sapiens Protein-associating with the carboxyl-terminal domain of ezrin Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000282346 Meles meles Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187488 Mycobacterium sp. Species 0.000 description 1
- 101100509674 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) katG3 gene Proteins 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 108010071726 N-hydroxyarylamine O-acetyltransferase Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000007456 Peroxiredoxin Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100026829 Protein-associating with the carboxyl-terminal domain of ezrin Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 108010048241 acetamidase Proteins 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 101150008083 ant gene Proteins 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 125000004050 enoyl group Chemical group 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 101150013110 katG gene Proteins 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108030002458 peroxiredoxin Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9811407.7 | 1998-05-27 | ||
| GBGB9811407.7A GB9811407D0 (en) | 1998-05-27 | 1998-05-27 | Mycobacterial N-Acetyltransferases |
| PCT/GB1999/001692 WO1999061625A1 (fr) | 1998-05-27 | 1999-05-27 | N-acetyltransferases mycobacteriennes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002516109A true JP2002516109A (ja) | 2002-06-04 |
Family
ID=10832803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000551009A Withdrawn JP2002516109A (ja) | 1998-05-27 | 1999-05-27 | マイコバクテリアのｎ−アセチルトランスフェラーゼ |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1082441A1 (fr) |
| JP (1) | JP2002516109A (fr) |
| GB (1) | GB9811407D0 (fr) |
| WO (1) | WO1999061625A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006057462A1 (fr) | 2004-11-29 | 2006-06-01 | Kirin Beer Kabushiki Kaisha | Migration de peptides dans un chromoplaste de metal et methode de construction de plantes possedant des petales jaunatres au moyen de ces peptides |
| CN110787164A (zh) * | 2019-10-08 | 2020-02-14 | 天津国际生物医药联合研究院 | 奥替尼啶在抑制乙酰基转移酶和抗分枝杆菌感染中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05260980A (ja) * | 1992-03-23 | 1993-10-12 | Tokyo Met Gov Shinkei Kagaku Sogo Kenkyusho | ヒト・アリルアミンｎ−アセチル転移酵素遺伝子 |
| AU6949694A (en) * | 1993-05-13 | 1994-12-12 | Agresearch Limited | Use of genes of m. tuberculosis, m. bovis and m. smegmatis which confer isoniazid resistance |
-
1998
- 1998-05-27 GB GBGB9811407.7A patent/GB9811407D0/en not_active Ceased
-
1999
- 1999-05-27 JP JP2000551009A patent/JP2002516109A/ja not_active Withdrawn
- 1999-05-27 EP EP99925163A patent/EP1082441A1/fr not_active Withdrawn
- 1999-05-27 WO PCT/GB1999/001692 patent/WO1999061625A1/fr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999061625A1 (fr) | 1999-12-02 |
| EP1082441A1 (fr) | 2001-03-14 |
| GB9811407D0 (en) | 1998-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6399337B1 (en) | α1,3-fucosyltransferase | |
| US5700683A (en) | Virulence-attenuating genetic deletions deleted from mycobacterium BCG | |
| US5441880A (en) | Human cdc25 genes, encoded products and uses thereof | |
| Williams et al. | Cloning and sequencing of the genes for the proton-translocating nicotinamide nucleotide transhydrogenase from Rhodospirillum rubrum and the implications for the domain structure of the enzyme | |
| Lioliou et al. | Phosphorylation activity of the response regulator of the two-component signal transduction system AtoS–AtoC in E. coli | |
| US5677428A (en) | RNA editing enzyme and methods of use thereof | |
| KR100938308B1 (ko) | 장내 세균의 검출 및 동정 | |
| US6428971B1 (en) | Teichoic acid enzymes and assays | |
| JP2002531130A (ja) | ＥｓｃｈｅｒｉｃｈｉａｃｏｌｉＯ１５７：Ｈ７と他の株とを識別する多形遺伝子座 | |
| EP1865063A1 (fr) | Mutant de glutamate décarboxylase | |
| JP2002516109A (ja) | マイコバクテリアのｎ−アセチルトランスフェラーゼ | |
| JP2001054387A (ja) | 改良されたｒｎａポリメラーゼ | |
| US6921641B2 (en) | Thermostable UvrA and UvrB polypeptides and methods of use | |
| US7001757B1 (en) | Protein | |
| YOO et al. | Determination of the native form of FadD, the Escherichia coli fatty acyl-CoA synthetase, and characterization of limited proteolysis by outer membrane protease OmpT | |
| JP4232423B2 (ja) | 新規ユビキチン特異プロテアーゼ | |
| US6492131B1 (en) | Class I-type lysyl-TRNA synthetase | |
| CN100497619C (zh) | 鞘脂神经酰胺脱酰基酶基因 | |
| AU2001278935A1 (en) | Novel DNA polymerase iii holoenzyme delta subunit nucleic acid molecules and proteins | |
| EP1301631A1 (fr) | Nouvelles proteines et molecules d'acides nucleiques de sous-unites d'adn polymerase iii/holoenzyme delta | |
| JP4171805B2 (ja) | 糖転移酵素 | |
| JP2002338595A (ja) | ＤｎａＡ蛋白質とＡＴＰとの親和性を利用した、病原性細菌の染色体ＤＮＡ複製開始蛋白質ＤｎａＡの精製方法、並びに、ＤｎａＡ蛋白質とＡＴＰとの親和性を利用した、抗菌活性の評価方法および抗菌活性を有する化合物のスクリーニング方法 | |
| McBride | Eukaryotic protein synthesis initiation factor eIF-4D: The hypusine-containing protein | |
| Stark | Genetic and genomic analyses of the Saccharomyces cerevisiae transcript elongation factor, TFIIS | |
| JP2005520518A (ja) | ＵＧＰＰａｓｅの製造 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20060801 |